{"content":"<li class=\"n-box-item date-title\" data-end=\"1472615999\" data-start=\"1472529600\" data-txt=\"Sunday, December 22, 2019\">Tuesday, August 30, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3206254\" data-ts=\"1472605302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OOMA\" target=\"_blank\">OOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206254-oomaplus-1_9-after-subscription-growth-paces-q2-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ooma +1.9% after subscription growth paces Q2 beat</a></h4><ul>   <li>Ooma (<a href=\"https://seekingalpha.com/symbol/OOMA\" title=\"Ooma\">OOMA</a> <font color=\"red\">-1.3%</font>) <font color=\"green\">rose 1.9%</font> after hours after it beat on top and bottom lines in its <a href=\"https://seekingalpha.com/news/3206210-ooma-beats-0_03-beats-revenue\" target=\"_blank\">Q2 results</a>.</li>    <li>Revenues grew nearly 21% paced by subscriptions and services, which more than made up for a decline in products. Ooma Office sales were up more than 60% Y/Y.</li>    <li>Net loss narrowed slightly, to $3.3M on a GAAP basis. Non-GAAP loss was $0.9M, vs. a year-ago loss of $2.5M.</li>    <li>Revenue by segment: Subscription and services, $22.4M (up 28%); Product and other, $3.1M (down 17%).</li>    <li>For Q3, it's guiding to revenues of $26.5M-$27.5M (vs. consensus for $27.2M) and non-GAAP net loss per share of $0.04 to $0.06 (vs. an expected loss per share of $0.06). For the full year, it's forecasting revenue of $104M-$107M (vs. $105.3M consensus) and non-GAAP net loss per share of $0.20 to $0.25 (vs. expected loss per share of $0.25).</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3206254\" data-linked=\"Ooma +1.9% after subscription growth paces Q2 beat\" data-tweet=\"$OOMA - Ooma +1.9% after subscription growth paces Q2 beat https://seekingalpha.com/news/3206254-oomaplus-1_9-after-subscription-growth-paces-q2-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3206254-oomaplus-1_9-after-subscription-growth-paces-q2-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206251\" data-ts=\"1472603832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206251-globalstar-up-7_2-on-strategic-deal-carmanah-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar up 7.2% on strategic deal with Carmanah Technologies</a></h4><ul>   <li>Globalstar (<a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a> <font color=\"green\">+5.6%</font>) finished the after-hours session <font color=\"green\">up 7.2%</font>, after moving as high as <font color=\"green\">+11.8%</font>, after news of a strategic deal with Carmanah Technologies.</li>    <li>Carmanah, a specialist in energy-optimized LED and solar tech, will work with Globalstar on the design of solar-powered machine-to-machine solutions, and in turn will use Globalstar's low earth orbiting constellation for remote connectivity of its strategic products.</li>    <li>Solar power will support longer battery life, Globalstar says, as well as higher data transmission capability.</li>    <li>First products from the arrangement are expected to be ready for market in the middle of next year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206251\" data-linked=\"Globalstar up 7.2% on strategic deal with Carmanah Technologies\" data-tweet=\"$GSAT - Globalstar up 7.2% on strategic deal with Carmanah Technologies https://seekingalpha.com/news/3206251-globalstar-up-7_2-on-strategic-deal-carmanah-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3206251-globalstar-up-7_2-on-strategic-deal-carmanah-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206248\" data-ts=\"1472601713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVAV\" target=\"_blank\">AVAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206248-aerovironmentminus-12_1-drone-sales-continue-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AeroVironment -12.1% as drone sales continue slide</a></h4><ul>   <li>AeroVironment (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AVAV\" title=\"AeroVironment, Inc.\">AVAV</a>) headed south after hours, <font color=\"red\">-12.1%</font>, following <a href=\"https://seekingalpha.com/news/3206208-aerovironment-misses-0_34-misses-revenue\" target=\"_blank\">fiscal Q1 earnings</a> where it noted drone sales that continue to slide and a miss on top and bottom lines.</li>    <li>Revenues tumbled 23% paced by declines in unmanned aircraft systems sales, along with a drop in efficient energy systems. Net loss widened to $11.6M from a year-ago loss of $7M.</li>    <li>Funded backlog was $74.7M, vs. $65.8M at the end of last quarter.</li>    <li>Revenue breakout: Product sales, $15.7M (down 40.9%); Contract services, $20.5M (up 0.3%). By segment: Unmanned Aircraft Systems, $30.5M (down 24.1%); Efficient Energy Systems, $5.7M (down 16.9%).</li>    <li>For the full fiscal year, the company \"remains committed\" to revenues of $260M-$280M (vs. consensus for $270.3M) and EPS of $0.20-$0.35 (a wide berth encapsulating consensus for $0.29). \"Seasonally low first quarter revenue, lower than planned bookings and significant international opportunities requiring export license approval contribute to greater execution challenges.\"</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3206248\" data-linked=\"AeroVironment -12.1% as drone sales continue slide\" data-tweet=\"$AVAV - AeroVironment -12.1% as drone sales continue slide https://seekingalpha.com/news/3206248-aerovironmentminus-12_1-drone-sales-continue-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3206248-aerovironmentminus-12_1-drone-sales-continue-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206234\" data-ts=\"1472593051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206234-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/FE' title='FirstEnergy Corp'>FE</a> <font color='green'>+27.0%</font>. <a href='https://seekingalpha.com/symbol/CCUR' title='Concurrent Computer Corporation'>OTC:CCUR</a> <font color='green'>+8.0%</font>. <a href='https://seekingalpha.com/symbol/VEEV' title='Veeva Systems Inc.'>VEEV</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a> <font color='green'>+2.8%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a> <font color='red'>-12.9%</font>. <a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='red'>-9.1%</font>. <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='red'>-7.9%</font>. <a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a> <font color='red'>-6.0%</font>. <a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a> <font color='red'>-4.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206234\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$FE $CCUR $VEEV - After Hours Gainers / Losers https://seekingalpha.com/news/3206234-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3206234-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206233\" data-ts=\"1472592863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206233-medicines-companys-mid-stage-study-assessing-plaque-buster-mdcominus-216-falls-short-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Medicines Company&#39;s mid-stage study assessing plaque buster MDCO-216 falls short of criteria for early termination; shares off 8% after hours</a></h4><ul>\n<li>A Phase 2 proof-of-concept, double-blind, placebo-controlled randomized study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02678923?term=mdco-216&amp;rank=1\" target=\"_blank\">MILANO-PILOT</a>, assessing The Medicines Company's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MDCO\" title=\"The Medicines Company\">MDCO</a>) MDCO-216 for reducing atherosclerotic plaque burden failed to achieve the efficacy results necessary for an early end to the trial. In a report, the Independent Data Monitoring Committee recommended the study continue citing the inconclusiveness of the interim data from 40 subjects. Results from the full group of 120 patients will be presented at the American Heart Association Scientific Sessions in mid-November.</li>\n<li>MDCO-216 a complex of a recombinant protein, apolipoprotein A-1 Milano, and phospholipid (POPC). It mimics pre-beta high density lipoprotein (HDL) and induces cholesterol efflux (flowing out), the first step in the removal of deposited cholesterol from the walls of blood vessels (reverse cholesterol transport). The company wants to prove that it improves cardiovascular outcomes.</li>\n<li>Also on tap for the AHA in November is interim data from the Phase 2 ORION-1 study assessing PCSK9si in 501 patients with atherosclerotic cardiovascular disease and elevated LDL-C despite maximum tolerated doses of LDL-C-lowering drugs. The study is comparing the effects of different doses of PCSK9si as well as evaluating the potential for quarterly or bi-annual dosing. The primary endpoint is the percent change in LDL-C from baseline at Day 180.</li>\n<li>PCSK9si, a GalNAc-conjugated RNAi therapeutic that targets PCSK9, is under development for the treatment of high cholesterol (hypercholesterolemia). PCSK9si turns off PCSK9 synthesis in the liver which is different that anti-PCSK9 monoclonal antibodies [Amgen's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AMGN\" title=\"Amgen Inc.\">AMGN</a>) Repatha (evolocumab) and Sanofi (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SNY\" title=\"Sanofi\">SNY</a>)/Regeneron's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/REGN\" title=\"Regeneron Pharmaceuticals, Inc.\">REGN</a>) Praluent (alirocumab)] which bind to PCSK9 in the blood.</li>\n<li>MDCO is down<font color=\"red\"> 8%</font> after hours on light volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206233\" data-linked=\"The Medicines Company&#39;s mid-stage study assessing plaque buster MDCO-216 falls short of criteria for early termination; shares off 8% after hours\" data-tweet=\"$MDCO $MDCO $AMGN - The Medicines Company&#39;s mid-stage study assessing plaque buster MDCO-216 falls short of criteria for early termination; shares off 8% after hours https://seekingalpha.com/news/3206233-medicines-companys-mid-stage-study-assessing-plaque-buster-mdcominus-216-falls-short-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3206233-medicines-companys-mid-stage-study-assessing-plaque-buster-mdcominus-216-falls-short-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206217\" data-ts=\"1472589295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEEV\" target=\"_blank\">VEEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206217-veeva-systemsplus-3_75-q2-total-revenueplus-34-subscriptions-revenueplus-40\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veeva Systems +3.75%; Q2 total revenue +34%, subscriptions revenue +40%</a></h4><ul>\n<li>Operating income increased 28% Y/Y to $36.7M, net income increased 23% Y/Y to $22.3M.</li>\n<li>Projects Q3 revenue of $134.5M-$136M, operating income of $36.5M-$37.5M and fully diluted net income per share of $0.15-$0.16. Updates FY 2017 projections for revenue to $525M-$528M, operating income to $138M-$140M and fully diluted net income per share to $0.60-$0.61.</li>\n<li>Veeva Systems (NYSE:<a href=\"https://seekingalpha.com/symbol/VEEV\" title=\"Veeva Systems Inc.\">VEEV</a>) CEO Peter Gassner: \u201cWe're bringing new industry cloud solutions to market at a rapid pace to address significant customer needs with great cloud technology and truly unified systems. It\u2019s this innovation and proven track record of customer success that\u2019s fueling our outperformance and sets us up for a long runway of growth into the future.\"</li>\n<li><a href=\"https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;referrer=&amp;eventid=1205740&amp;sessionid=1&amp;key=412313A6CC61A23412C175F1C29A838C&amp;regTag=&amp;sourcepage=register\" target=\"_blank\">Conference call</a></li>\n<li><a href=\"https://seekingalpha.com/news/3206204-veeva-systems-beats-0_02-beats-revenue\" target=\"_blank\">Results</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206217\" data-linked=\"Veeva Systems +3.75%; Q2 total revenue +34%, subscriptions revenue +40%\" data-tweet=\"$VEEV - Veeva Systems +3.75%; Q2 total revenue +34%, subscriptions revenue +40% https://seekingalpha.com/news/3206217-veeva-systemsplus-3_75-q2-total-revenueplus-34-subscriptions-revenueplus-40?source=tweet\" data-url=\"https://seekingalpha.com/news/3206217-veeva-systemsplus-3_75-q2-total-revenueplus-34-subscriptions-revenueplus-40\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206194\" data-ts=\"1472588158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206194-palo-alto-networks-announces-500m-share-repurchase-amid-49-fiscal-year-revenue-56-billings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks announces $500M share repurchase amid 49% fiscal year revenue, 56% billings growth</a></h4><ul>\n<li>Palo Alto Networks (NYSE:<a href=\"https://seekingalpha.com/symbol/PANW\" title=\"Palo Alto Networks\">PANW</a>) is presently <font color=\"green\">up around 2%</font> in extended trading.</li>\n<li>Q4 <a href=\"https://seekingalpha.com/news/3206200-palo-alto-networks-eps-line-beats-revenue\" target=\"_blank\">revenue</a> increased 41% Y/Y to $400.8M. Q4 billings increased 45% to $572.4M.</li>\n<li>Projects Q1 2017 revenue of $396M-$402M (33%-35% Y/Y growth) and net income per share of $0.51-$0.53. Projects FY 2017 net income per share of $2.75-$2.80.</li>\n<li>CEO Mark McLaughlin: \"The security industry is seeing a rapid transformation from legacy hardware and point products to integrated and automated capabilities that seamlessly work together as a platform. As the primary innovator driving this paradigm shift, customers are turning to our Next-Generation Security Platform in record numbers to more effectively prevent cyberattacks no matter where their data resides.\"</li>\n<li><a href=\"http://edge.media-server.com/m/p/6gjd8nqt/lan/en\" target=\"_blank\">Conference call</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206194\" data-linked=\"Palo Alto Networks announces $500M share repurchase amid 49% fiscal year revenue, 56% billings growth\" data-tweet=\"$PANW - Palo Alto Networks announces $500M share repurchase amid 49% fiscal year revenue, 56% billings growth https://seekingalpha.com/news/3206194-palo-alto-networks-announces-500m-share-repurchase-amid-49-fiscal-year-revenue-56-billings?source=tweet\" data-url=\"https://seekingalpha.com/news/3206194-palo-alto-networks-announces-500m-share-repurchase-amid-49-fiscal-year-revenue-56-billings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206198\" data-ts=\"1472587183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206198-worker-dies-freeport-copper-mine-in-chile-operations-halted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Worker dies at Freeport copper mine in Chile; some operations halted</a></h4><ul>     <li>A worker <a href=\"http://www.reuters.com/article/freeport-mcmoran-chile-accident-idUSL1N1BB0U8\" target=\"_blank\">died</a> after an accident at Freeport McMoRan's (<a href=\"https://seekingalpha.com/symbol/FCX\" title=\"Freeport-McMoRan Inc.\">FCX</a> <font color=\"red\">-4.2%</font>) majority owned El Abra copper mine in Chile, forcing a halt to some operations.</li>     <li>The worker reportedly died from injuries suffered at the acid unloading terminal, where operations have been suspended.</li>     <li>El Abra is 51% owned by FCX, with state-run Codelco owning 49%, and produced ~147K metric tons of copper last year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206198\" data-linked=\"Worker dies at Freeport copper mine in Chile; some operations halted\" data-tweet=\"$FCX - Worker dies at Freeport copper mine in Chile; some operations halted https://seekingalpha.com/news/3206198-worker-dies-freeport-copper-mine-in-chile-operations-halted?source=tweet\" data-url=\"https://seekingalpha.com/news/3206198-worker-dies-freeport-copper-mine-in-chile-operations-halted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206193\" data-ts=\"1472587076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206193-intelsatminus-9_3-following-141_8m-debt-exchange-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat -9.3% following $141.8M debt exchange offer</a></h4><ul>   <li>Intelsat (NYSE:<a href=\"https://seekingalpha.com/symbol/I\" title=\"Intelsat SA\">I</a>) has <font color=\"red\">slid 9.3%</font> today on relatively heavy volume after it set up a <a href=\"http://www.bloomberg.com/news/articles/2016-08-30/intelsat-offers-cash-and-2024-bonds-to-retire-debt-due-in-2022\" target=\"_blank\">$141.8M bond exchange</a>, another attempt to cut heavy debt that piled up through leveraged buyouts.</li>    <li>The company's offering $120 in cash ($100 after Sept. 12) and $705 in 8% notes due 2024 for each $1,000 of its existing 6.625% notes due December 2022, and it says it's seeing participation from holders of $78.4M of the old notes.</li>    <li>That means a premium for investors, but also the chance for Intelsat to strip bond covenants.</li>    <li>The exchange offer expires Sept. 26.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206193\" data-linked=\"Intelsat -9.3% following $141.8M debt exchange offer\" data-tweet=\"$I - Intelsat -9.3% following $141.8M debt exchange offer https://seekingalpha.com/news/3206193-intelsatminus-9_3-following-141_8m-debt-exchange-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3206193-intelsatminus-9_3-following-141_8m-debt-exchange-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206189\" data-ts=\"1472585865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIPT\" target=\"_blank\">AIPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206189-skyline-medical-to-form-joint-venture-to-access-u-s-government-contracts-shares-up-109\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyline Medical to form joint venture to access U.S. government contracts; shares up 109%</a></h4><ul>\n<li>Nano cap Skyline Medical (SKLN <font color=\"green\">+108.5%</font>) inks a letter of intent with Electronic On-Ramp (EOR) to form a joint venture with the aim of securing access to bid on U.S. government contracts valued up to $550M or more. EOR is a certified Small Disadvantaged Business owned by a Service Disabled Veteran which provides access to such bids as a qualified government contractor.</li>\n<li>Under the terms of the agreement, which has yet to be approved by Skyline shareholders, EOR will own 51% of the JV and Skyline 49%. Other financial terms are not disclosed.</li>\n<li>Skyline intends to sell its STREAMWAY System through the JV in addition to sourcing other medical products to fulfill the bids. The two primary contracts EOR will focus on to promote Skyline's products are the GSA Information Technology Schedule 70 and the Security and Life Safety Schedule 84. EOR has already been awarded two contracts: one to provide government-wide health-related security, technology and information support and one to provide operating room and medical equipment for disaster relief in North and South America with the U.S. Southern and Northern Commands.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206189\" data-linked=\"Skyline Medical to form joint venture to access U.S. government contracts; shares up 109%\" data-tweet=\"$AIPT $POAI - Skyline Medical to form joint venture to access U.S. government contracts; shares up 109% https://seekingalpha.com/news/3206189-skyline-medical-to-form-joint-venture-to-access-u-s-government-contracts-shares-up-109?source=tweet\" data-url=\"https://seekingalpha.com/news/3206189-skyline-medical-to-form-joint-venture-to-access-u-s-government-contracts-shares-up-109\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206115\" data-ts=\"1472584388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMPV\" target=\"_blank\">IMPV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206115-imperva-downgraded-pacific-crest-securities-turnaround-away-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imperva downgraded at Pacific Crest Securities; turnaround further away than expected</a></h4><ul>\n<li>Analyst Rob Owens: \"While management had previously attributed its success and strong pipeline build to its depth of management and vigilance building pipeline, the majority of the team praised on the fourth quarter conference call are no longer with the company.\"</li>\n<li>He <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/08/8404840/pacific-crest-downgrades-imperva-expects-longer-than-exp\" target=\"_blank\">downgrades</a> Imperva (<a href=\"https://seekingalpha.com/symbol/IMPV\" title=\"Imperva, Inc.\">IMPV</a> <font color=\"red\">-2.4%</font>) to Sector Weight on those management concerns, challenged fundamentals and pressure the company would see if it doesn't realize any strategic alternatives it declared to be pursuing in its inadequate Q2 report.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206115\" data-linked=\"Imperva downgraded at Pacific Crest Securities; turnaround further away than expected\" data-tweet=\"$IMPV - Imperva downgraded at Pacific Crest Securities; turnaround further away than expected https://seekingalpha.com/news/3206115-imperva-downgraded-pacific-crest-securities-turnaround-away-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3206115-imperva-downgraded-pacific-crest-securities-turnaround-away-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206183\" data-ts=\"1472583637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206183-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> ATMR <font color=\"green\">+16%</font>. <a href=\"https://seekingalpha.com/symbol/AEHR\" title=\"Aehr Test Systems\">AEHR</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/ITI\" title=\"Iteris, Inc\">ITI</a> <font color=\"green\">+8%</font>. <a href=\"https://seekingalpha.com/symbol/RESN\" title=\"Resonant\">RESN</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/HEAR\" title=\"Turtle Beach Corporation\">HEAR</a> <font color=\"green\">+6%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/SCSC\" title=\"ScanSource, Inc.\">SCSC</a> <font color=\"red\">-17%</font>. <a href=\"https://seekingalpha.com/symbol/CBAK-OLD\" title=\"China BAK Battery, Inc.\">CBAK-OLD</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/SHSP\" title=\"SharpSpring, Inc.\">SHSP</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/I\" title=\"Intelsat SA\">I</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/HMNY\" title=\"Helios and Matheson Analytics, Inc.\">HMNY</a> <font color=\"red\">-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206183\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$ATOM $AEHR $ITI - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3206183-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3206183-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206182\" data-ts=\"1472583498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206182-bhp-billiton-withholds-annual-bonus-from-ceo-mackenzie\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BHP Billiton withholds annual bonus from CEO Mackenzie</a></h4><ul>     <li>BHP Billiton&rsquo;s (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-1.9%</font>) board has <a href=\"http://www.marketwatch.com/story/bhp-billiton-scraps-ceos-bonus-2016-08-30\" target=\"_blank\">scrapped CEO Andrew Mackenzie's bonus</a> for the year ended June 30 and has cut the bonuses of other senior BHP executives by varying amounts.</li>     <li>The move comes after BHP reported a net loss of $6.39B for the 12 months through June, brought on partly by the catastrophic Brazil mining dam failure that killed 19 people.</li>     <li>Mackenzie earned a salary of $1.7M last year, an amount that has been frozen since he took over as CEO in 2013, and BHP last year paid $2.3M to Mackenzie as a bonus, half in cash and half in deferred shares due to vest in FY 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206182\" data-linked=\"BHP Billiton withholds annual bonus from CEO Mackenzie\" data-tweet=\"$BHP - BHP Billiton withholds annual bonus from CEO Mackenzie https://seekingalpha.com/news/3206182-bhp-billiton-withholds-annual-bonus-from-ceo-mackenzie?source=tweet\" data-url=\"https://seekingalpha.com/news/3206182-bhp-billiton-withholds-annual-bonus-from-ceo-mackenzie\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206173\" data-ts=\"1472581489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206173-cypress-semiconductorplus-6-private-equity-takeover-speculated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cypress Semiconductor +6%; private-equity takeover speculated</a></h4><ul>\n<li>While nothing material is confirmed to have transpired, shares of Cypress Semiconductor (<a href=\"https://seekingalpha.com/symbol/CY\" title=\"Cypress Semiconductor Corporation\">CY</a> <font color=\"green\">+6%</font>) are elevated on a <a href=\"http://www.streetinsider.com/Hot+M+and+A/TPG+Capital+Said+Willing+to+Pay+Up+to+%2415+Per+Share+to+Acquire+Cypress+%28CY%29+-+Source/11986648.html\" target=\"_blank\">rumor</a> <a href=\"http://www.tpg.com/\" target=\"_blank\">TPG Capital</a> could be ready to offer $15 per share in a buyout.</li>\n<li>Shares are trading at a 9.64M volume level over a 6.25M average.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206173\" data-linked=\"Cypress Semiconductor +6%; private-equity takeover speculated\" data-tweet=\"$CY - Cypress Semiconductor +6%; private-equity takeover speculated https://seekingalpha.com/news/3206173-cypress-semiconductorplus-6-private-equity-takeover-speculated?source=tweet\" data-url=\"https://seekingalpha.com/news/3206173-cypress-semiconductorplus-6-private-equity-takeover-speculated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206170\" data-ts=\"1472580183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206170-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='green'>+28%</font>. POT <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AAU' title='Almaden Minerals Ltd'>AAU</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FSM' title='Fortuna Silver Mines'>FSM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206170\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$PQ $NTR $IPI - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3206170-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3206170-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206162\" data-ts=\"1472576415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206162-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/EMITF' title='Elbit Imaging Ltd.'>EMITF</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3206162\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$PMTS $EMITF $FSAM - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3206162-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3206162-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206158\" data-ts=\"1472576009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206158-confidence-fades-in-apparel-store-turnaround\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Confidence fades in apparel store turnaround</a></h4><ul>\n<li>A warning from Abercrombie &amp; Fitch (<a href=\"https://seekingalpha.com/symbol/ANF\" title=\"Abercrombie &amp; Fitch\">ANF</a> <font color=\"red\">-20.6%</font>) on second-half comparable sales is resonating across the jittery apparel store sector, along with weak reports from DSW (<a href=\"https://seekingalpha.com/symbol/DSW\" title=\"DSW Inc.\">DSW</a> <font color=\"red\">-10.3%</font>) and Christopher &amp; Banks (<a href=\"https://seekingalpha.com/symbol/CBK\" title=\"Christopher &amp; Banks Corporation\">CBK</a> <font color=\"red\">-19.7%</font>).</li>\n<li>Ascena Retail Group (<a href=\"https://seekingalpha.com/symbol/ASNA\" title=\"Ascena Retail Group Inc\">ASNA</a> <font color=\"red\">-6.6%</font>), Stage Stores (<a href=\"https://seekingalpha.com/symbol/SSI\" title=\"Stage Stores, Inc.\">SSI</a> <font color=\"red\">-5.1%</font>), Guess (<a href=\"https://seekingalpha.com/symbol/GES\" title=\"Guess? Inc.\">GES</a> <font color=\"red\">-3.8%</font>), Chico's FAS (<a href=\"https://seekingalpha.com/symbol/CHS\" title=\"Chico's FAS, Inc.\">CHS</a> <font color=\"red\">-3%</font>), and Francesca's (<a href=\"https://seekingalpha.com/symbol/FRAN\" title=\"Francesca's Holdings Corp.\">FRAN</a> <font color=\"red\">-2.8%</font>) are all notably lower after the gloomy sector updates.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3206050-abercrombie-and-fitch-falls-hard-weak-outlook\" target=\"_blank\">Abercrombie &amp; Fitch falls hard after weak outlook</a> (Aug. 30)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3206073-sales-fall-short-christopher-and-banks\" target=\"_blank\">Sales fall short at Christopher &amp; Banks</a> (Aug. 30)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3206029-dsw-sets-line-profit-guidance\" target=\"_blank\">DSW sets in-line profit guidance</a> (Aug. 30)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206158\" data-linked=\"Confidence fades in apparel store turnaround\" data-tweet=\"$ANF $ANF $DBI - Confidence fades in apparel store turnaround https://seekingalpha.com/news/3206158-confidence-fades-in-apparel-store-turnaround?source=tweet\" data-url=\"https://seekingalpha.com/news/3206158-confidence-fades-in-apparel-store-turnaround\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206157\" data-ts=\"1472575662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206157-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+53%</font>. <a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/RBA' title='Ritchie Bros. Auctioneers Inc.'>RBA</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/YECO-OLD' title='Yulong Eco-Materials'>YECO-OLD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AEHR' title='Aehr Test Systems'>AEHR</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PAHC' title='Phibro Animal Health Corporation'>PAHC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/CBK' title='Christopher & Banks Corporation'>CBK</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-19%</font>. ADHD <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SCSC' title='ScanSource, Inc.'>SCSC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/STAF' title='Staffing 360 Solutions, Inc.'>STAF</a> <font color='red'>-15%</font>. MIRN <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/LIME-OLD' title='lime energy co.'>LIME</a> <font color='red'>-13%</font>. MCUR <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/EGLE' title='Eagle Bulk Shipping Inc.'>EGLE</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206157\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$RIGL $KPTI $VRAY - Midday Gainers / Losers https://seekingalpha.com/news/3206157-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3206157-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206156\" data-ts=\"1472575071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206156-potential-potash-agrium-merger-makes-no-sense-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potential Potash-Agrium merger makes no sense, analyst says</a></h4><ul>     <li>Trading resumes in Potash Corp. (POT <font color=\"green\">+10.4%</font>) and Agrium (AGU <font color=\"green\">+5.8%</font>) after the fertilizer companies <a href=\"https://seekingalpha.com/news/3206148-potash-agrium-confirm-preliminary-merger-talks\" target=\"_blank\">confirm</a> they are in preliminary talks about a possible merger.</li>     <li>At least one analyst thinks a POT-AGU combination <a href=\"https://twitter.com/amberkanwar/status/770650922162806784\" target=\"_blank\">would make no sense</a>; Cowen's Amber Kanwar says both companies largely have completed their expansion plans, so a merger would not change the capex outcome in any meaningful way.</li>     <li>Kanwar believes a merger would not substantially impact the market and continues to see excess capacity in potash, nitrogen and phosphate as an issue going forward.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206156\" data-linked=\"Potential Potash-Agrium merger makes no sense, analyst says\" data-tweet=\"$NTR - Potential Potash-Agrium merger makes no sense, analyst says https://seekingalpha.com/news/3206156-potential-potash-agrium-merger-makes-no-sense-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3206156-potential-potash-agrium-merger-makes-no-sense-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206145\" data-ts=\"1472572830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206145-consumer-goods-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer Goods - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/HSY' title='The Hershey Company'>HSY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BREW' title='Craft Brew Alliance Inc'>BREW</a> <font color='red'>-6%</font>. SPU <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3206145\" data-linked=\"Consumer Goods - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SORL $ZXAIY $GIII - Consumer Goods - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3206145-consumer-goods-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3206145-consumer-goods-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206148\" data-ts=\"1472572624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206148-potash-agrium-confirm-preliminary-merger-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potash, Agrium confirm preliminary merger talks</a></h4><ul>     <li>Potash Corp. (POT <font color=\"green\">+13.4%</font>) and Agrium (AGU <font color=\"green\">+7.9%</font>) say they are in preliminary discussions regarding a potential merger of equals, confirming an <a href=\"https://seekingalpha.com/news/3206113-potash-agrium-surge-report-merger-talks\" target=\"_blank\">earlier report</a>; shares are halted again.</li>     <li>The companies caution that no decision has been made and no agreement has been reached.</li>     <li>Fertilizer producers have been hurt in recent years by depressed prices for crop nutrients amid a glut of supply and weak demand, and both companies have cut their 2016 earnings guidance.</li>     <li>Before the trading halt, POT shares soared for their biggest gain in six years while AGU climbed more than 7%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206148\" data-linked=\"Potash, Agrium confirm preliminary merger talks\" data-tweet=\"$NTR - Potash, Agrium confirm preliminary merger talks https://seekingalpha.com/news/3206148-potash-agrium-confirm-preliminary-merger-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3206148-potash-agrium-confirm-preliminary-merger-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206147\" data-ts=\"1472572511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206147-morning-slide-for-oil-takes-stocks-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morning slide for oil takes stocks lower</a></h4><ul><li>WTI crude oil has tumbled more than $1 per barrel since about 10 ET, now&nbsp;<font color='red'>off 1.3%</font>&nbsp;on the session at $46.38.</li><li>The move has taken the gas out of an early rally in energy names (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>), and helped bring the S&amp;P 500 modestly into the red for the day.</li><li><a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>&nbsp;<font color='red'>-1.1%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3206147\" data-linked=\"Morning slide for oil takes stocks lower\" data-tweet=\"$XLE $USO - Morning slide for oil takes stocks lower https://seekingalpha.com/news/3206147-morning-slide-for-oil-takes-stocks-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3206147-morning-slide-for-oil-takes-stocks-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206140\" data-ts=\"1472570377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTFT\" target=\"_blank\">FTFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206140-volatile-way-continue-for-sky-people-fruit-juice\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatile way continue for Sky People Fruit Juice</a></h4><ul><li>Shares of Sky People Fruit Juice (SPU <font color='red'>-4%</font>) fall off after Geo Investing <a href=\"http://geoinvesting.com/spu-ground-due-diligence/\" target=\"_blank\">warns</a>&nbsp;in a fresh note to investors that the company is \"pumping again.\"</li><li>Sky People soared over 50% yesterday to jump back over $10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3206140\" data-linked=\"Volatile way continue for Sky People Fruit Juice\" data-tweet=\"$FTFT - Volatile way continue for Sky People Fruit Juice https://seekingalpha.com/news/3206140-volatile-way-continue-for-sky-people-fruit-juice?source=tweet\" data-url=\"https://seekingalpha.com/news/3206140-volatile-way-continue-for-sky-people-fruit-juice\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206104\" data-ts=\"1472569277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206104-healthcare-top-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> ADHD <font color='red'>-13%</font>. MCUR <font color='red'>-9%</font>. NEOT <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NYMX' title='Nymox Pharmaceutical Corporation'>NYMX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3206104\" data-linked=\"Healthcare - Top Gainers / Losers as of 11:00 am\" data-tweet=\"$RIGL $KPTI $SYRS - Healthcare - Top Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3206104-healthcare-top-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3206104-healthcare-top-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206124\" data-ts=\"1472569113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206124-airline-sector-given-lift-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline sector given a lift by investors</a></h4><ul>\n<li>Airline stocks are higher as investors take a hard look at the sector seen by some analysts as undervalued.</li>\n<li>On the macroeconomic front, a read on consumer confidence came in very positive today and oil prices are cooperating, while on the corporate site a <a href=\"https://seekingalpha.com/news/3206094-deepening-management-bench-united-continental-seen-positive\" target=\"_blank\">major hire</a> at United Continental (<a href=\"https://seekingalpha.com/symbol/UAL\" title=\"United Continental Holdings, Inc\">UAL</a> <font color=\"green\">+7.8%</font>) is being well-received.</li>\n<li>Notable gainers include SkyWest (<a href=\"https://seekingalpha.com/symbol/SKYW\" title=\"SkyWest, Inc.\">SKYW</a> <font color=\"green\">+2.7%</font>), Allegiant Travel (<a href=\"https://seekingalpha.com/symbol/ALGT\" title=\"Allegiant Travel Company\">ALGT</a> <font color=\"green\">+2.1%</font>), American Airlines Group (<a href=\"https://seekingalpha.com/symbol/AAL\" title=\"American Airlines Group\">AAL</a> <font color=\"green\">+1.9%</font>), and Delta Air Lines (<a href=\"https://seekingalpha.com/symbol/DAL\" title=\"Delta Air Lines, Inc.\">DAL</a> <font color=\"green\">+1.6%</font>).</li>\n<li>Related ETF: <a href=\"https://seekingalpha.com/symbol/JETS\" title=\"U.S. Global Jets ETF\">JETS</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206124\" data-linked=\"Airline sector given a lift by investors\" data-tweet=\"$UAL $UAL $SKYW - Airline sector given a lift by investors https://seekingalpha.com/news/3206124-airline-sector-given-lift-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3206124-airline-sector-given-lift-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206121\" data-ts=\"1472568506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KPTI\" target=\"_blank\">KPTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206121-karyopharm-up-22-selinexor-data-in-multiple-myeloma-expected-in-september\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karyopharm up 22%; selinexor data in multiple myeloma expected in September</a></h4><ul>\n<li>Thinly traded micro cap Karyopharm Therapeutics (<a href=\"https://seekingalpha.com/symbol/KPTI\" title=\"Karyopharm Therapeutics Inc.\">KPTI</a> <font color=\"green\">+22.2%</font>) heads north on more than a 4x surge in volume. No particular news accounts for the high volume action although investors may be starting to build positions ahead of the release of data from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02336815?term=selinexor&amp;cond=multiple+myeloma&amp;rank=5\" target=\"_blank\">STORM</a>, assessing lead product candidate selinexor in treatment-resistant multiple myeloma. Top-line results should be available in September.</li>\n<li>\n<a href=\"http://karyopharm.com/drug-candidate/oral_selinexor_kpt-330/\" target=\"_blank\">Selinexor </a>is a SINE (Selective Inhibitor of Nuclear Export) compound. It binds to and inhibits the nuclear export protein XPO1 which leads to the accumulation of tumor suppressor proteins in the cell nucleus which amplifies tumor suppression. It is also under development for the treatment of liposarcoma, diffuse large B-cell lymphoma and acute myeloid leukemia.</li>\n<li>Today, Jefferies upgraded to stock to Buy from Hold with a $12 (37% upside) price target based on the expectation of positive STORM results.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206121\" data-linked=\"Karyopharm up 22%; selinexor data in multiple myeloma expected in September\" data-tweet=\"$KPTI - Karyopharm up 22%; selinexor data in multiple myeloma expected in September https://seekingalpha.com/news/3206121-karyopharm-up-22-selinexor-data-in-multiple-myeloma-expected-in-september?source=tweet\" data-url=\"https://seekingalpha.com/news/3206121-karyopharm-up-22-selinexor-data-in-multiple-myeloma-expected-in-september\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206114\" data-ts=\"1472567033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BETR\" target=\"_blank\">BETR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206114-amplify-snack-brands-pops-to-post-ipo-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amplify Snack Brands pops to post-IPO high</a></h4><ul> <li>Amplify Snack Brands (NYSE:<a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a>) is <font color='green'>up 3.44%</font> to hit a post-IPO high of $17.04.</li> <li>There's no major corporate news or SEC filings out on Amplify, but Mondelez International scuttling its talks with Hershey has launched a bit of a reset in the food sector.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3206114\" data-linked=\"Amplify Snack Brands pops to post-IPO high\" data-tweet=\"$BETR $BETR-OLD - Amplify Snack Brands pops to post-IPO high https://seekingalpha.com/news/3206114-amplify-snack-brands-pops-to-post-ipo-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3206114-amplify-snack-brands-pops-to-post-ipo-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206113\" data-ts=\"1472566912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206113-potash-agrium-surge-on-report-of-merger-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potash, Agrium surge on report of merger talks</a></h4><ul>     <li>Potash Corp. (POT <font color='green'>+12.3%</font>) and Agrium (AGU <font color='green'>+6.6%</font>) resume trading after a halt for volatility following a Bloomberg report that the companies are in <a href=\"http://www.bloomberg.com/news/articles/2016-08-30/canada-s-potash-agrium-said-in-advanced-talks-about-merger\" target=\"_blank\">advanced merger talks</a>.</li>     <li>A combination reportedly could be announced as soon as next week, although no final decisions have been made.</li>     <li>Related stocks also are ticking higher: <a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='green'>+7.3%</font>, <a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='green'>+4.4%</font>, <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+13.7%</font>, <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+3.1%</font>, <a href='https://seekingalpha.com/symbol/UAN' title='CVR Partners, LP'>UAN</a> <font color='green'>+3.3%</font>, <a href='https://seekingalpha.com/symbol/TNH' title='Terra Nitrogen Co. LP'>TNH</a> <font color='green'>+2.3%</font>, <a href='https://seekingalpha.com/symbol/ICL' title='Israel Chemicals Ltd.'>ICL</a> <font color='green'>+3.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206113\" data-linked=\"Potash, Agrium surge on report of merger talks\" data-tweet=\"$NTR $NTR $MOS - Potash, Agrium surge on report of merger talks https://seekingalpha.com/news/3206113-potash-agrium-surge-on-report-of-merger-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3206113-potash-agrium-surge-on-report-of-merger-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206111\" data-ts=\"1472566599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206111-micron-technology-price-target-increased-morgan-stanley-overweight-rating-reissued\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology price target increased at Morgan Stanley, Overweight rating reissued</a></h4><ul>\n<li>Target to $20 up from $18 (current price $16.98).</li>\n<li>While remaining <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/08/8404604/morgan-stanley-raises-microns-price-target-to-20-on-manu\" target=\"_blank\">positive overall</a> on Micron Technology (<a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a> <font color=\"red\">-0.2%</font>), analyst Joseph Moore does note some possible upcoming supply volatility.</li>\n<li>Micron received <a href=\"https://seekingalpha.com/news/3205782-micron-price-target-lifted-deutsche-stifel\" target=\"_blank\">upgraded targets</a> yesterday at Deutsche Bank and Stifel Nicolaus, and <a href=\"https://seekingalpha.com/news/3205418-micron-technology-plus-6-percent-western-digital-plus-3-percent-following-hp-component\" target=\"_blank\">gained traction</a> on <a href=\"https://seekingalpha.com/article/4001943-hps-hpq-ceo-dion-weisler-q3-2016-results-earnings-call-transcript\" target=\"_blank\">comments</a> by HP's CEO last week citing component shortages.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206111\" data-linked=\"Micron Technology price target increased at Morgan Stanley, Overweight rating reissued\" data-tweet=\"$MU - Micron Technology price target increased at Morgan Stanley, Overweight rating reissued https://seekingalpha.com/news/3206111-micron-technology-price-target-increased-morgan-stanley-overweight-rating-reissued?source=tweet\" data-url=\"https://seekingalpha.com/news/3206111-micron-technology-price-target-increased-morgan-stanley-overweight-rating-reissued\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206082\" data-ts=\"1472562930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206082-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/RIGL\" title=\"Rigel Pharmaceuticals, Inc.\">RIGL</a> <font color=\"green\">+21%</font>. <a href=\"https://seekingalpha.com/symbol/OREX\" title=\"Orexigen Therapeutics, Inc.\">OREX</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/RBA\" title=\"Ritchie Bros. Auctioneers Inc.\">RBA</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/KMDA\" title=\"Kamada Ltd\">KMDA</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/SPHS\" title=\"Sophiris Bio\">SPHS</a> <font color=\"green\">+6%</font>. SPU <font color=\"green\">+6%</font>. THLD <font color=\"green\">+6%</font>.</li> <li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/GIII\" title=\"G-III Apparel Group, LTD.\">GIII</a> <font color=\"red\">-20%</font>. <a href=\"https://seekingalpha.com/symbol/ANF\" title=\"Abercrombie &amp; Fitch\">ANF</a> <font color=\"red\">-14%</font>. <a href=\"https://seekingalpha.com/symbol/HSY\" title=\"The Hershey Company\">HSY</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/ISLE\" title=\"Isle of Capri Casinos, Inc.\">ISLE</a> <font color=\"red\">-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3206082\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$RIGL $OREX $RBA - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3206082-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3206082-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206081\" data-ts=\"1472562759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206081-array-bios-arryminus-797-shows-encouraging-results-in-mid-stage-study-in-rare-heart-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array Bio&#39;s ARRY-797 shows encouraging results in mid-stage study in rare heart disorder; shares up 7% premarket</a></h4><ul>\n<li>Micro cap Array BioPharma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ARRY\" title=\"Array BioPharma Inc.\">ARRY</a>) perks up <font color=\"green\">7%</font> premarket on increased volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1100412/000114420416121874/v447890_ex99-1.htm\" target=\"_blank\">announcement </a>of positive results in a Phase 2 clinical trial assessing ARRY-797 for the treatment of patients with lamin A/C-related dilated cardiomyopathy (LMNA-DCM), a rare degenerative cardiovascular disease caused by mutations in the LMNA gene that is associated with a poor prognosis. The data were presented at the European Society of Cardiology Congress in Rome.</li>\n<li>All patients in the open-label study had stable New York Heart Association class II-IIIa heart failure and eleven had an implanted cardiac defibrillator. They were randomized to receive either 100 mg or 400 mg of ARRY-797 twice daily for 12 weeks. All were also receiving multiple heart failure medications.</li>\n<li>The mean change from baseline in the six-minute walk test (6MWT), the primary endpoint, was 69 meters. Sustained improvement in related biomarkers was also observed. A trend for greater improvement was seen with the 400 mg dose.</li>\n<li>\n<a href=\"http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-797/\" target=\"_blank\">ARRY-797</a> is an oral p38 mitogen-activated protein kinase (MAPK) inhibitor. The genetic mutations in LMNA-DCM lead to a loss of functional lamin proteins that activates the p38 MAPK pathway which leads to cardiac cell death and cardiac tissue <a href=\"https://en.wikipedia.org/wiki/Ventricular_remodeling\" target=\"_blank\">remodeling</a> (changes in the heart's size, structure and physiology). This degrades the performance of the heart over time and eventually leads to failure. Inhibiting MAPK can potentially reverse cardiac remodeling and improve heart function.</li>\n<li>The company has met with regulators to discuss the design of a pivotal study to support a marketing application. It is also evaluating its options for development, including partnering, creating a separate company focused solely on the asset or advancing it on its own.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206081\" data-linked=\"Array Bio&#39;s ARRY-797 shows encouraging results in mid-stage study in rare heart disorder; shares up 7% premarket\" data-tweet=\"$ARRY - Array Bio&#39;s ARRY-797 shows encouraging results in mid-stage study in rare heart disorder; shares up 7% premarket https://seekingalpha.com/news/3206081-array-bios-arryminus-797-shows-encouraging-results-in-mid-stage-study-in-rare-heart-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3206081-array-bios-arryminus-797-shows-encouraging-results-in-mid-stage-study-in-rare-heart-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206070\" data-ts=\"1472560788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OREX\" target=\"_blank\">OREX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206070-orexigen-inks-deal-valeant-for-commercialization-of-contrave-in-canada-shares-up-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orexigen inks deal with Valeant for commercialization of Contrave in Canada; shares up 11% premarket</a></h4><ul>\n<li>Thinly traded nano cap Orexigen Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OREX\" title=\"Orexigen Therapeutics, Inc.\">OREX</a>) is ahead <font color=\"green\">11% </font>premarket, albeit on only 11,300 shares, in response to its announcement that it has signed an agreement with Valeant Pharmaceuticals (VRX) unit Valeant Canada for the commercialization of obesity med Contrave (naltrexone HCl) in Canada.</li>\n<li>Under the terms of the deal, Valeant Canada will be responsible for securing Canadian regulatory approval and all commercialization activities and expenses. Orexigen will supply Contrave at a specific transfer price and will be eligible for certain regulatory- and sales-based milestone payments. Specific financial terms are not disclosed. The marketing application to Health Canada should be filed in January 2017.</li>\n<li>In March, the companies inked a commercialization deal for Mysimba (naltrexone HCl/bupropion HCl prolonged release) covering 19 countries in Central and Eastern Europe. The product will be launched in 11 of the countries in Q4, followed by two additional countries in Q1 2017.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206070\" data-linked=\"Orexigen inks deal with Valeant for commercialization of Contrave in Canada; shares up 11% premarket\" data-tweet=\"$OREX $OREX $BHC - Orexigen inks deal with Valeant for commercialization of Contrave in Canada; shares up 11% premarket https://seekingalpha.com/news/3206070-orexigen-inks-deal-valeant-for-commercialization-of-contrave-in-canada-shares-up-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3206070-orexigen-inks-deal-valeant-for-commercialization-of-contrave-in-canada-shares-up-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206069\" data-ts=\"1472560784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRED\" target=\"_blank\">FRED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206069-on-freds-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Fred&#39;s Q2</a></h4><ul>     <li>Fred's (<a href=\"https://seekingalpha.com/symbol/FRED\" title=\"Fred's, Inc.\">FRED</a>) reports comparable-store sales fell 2% in Q2.</li>     <li>Gross margin rate flat Y/Y at 24.2%.</li>     <li>SG&amp;A expense rate increased 60 bps to 24.1%.</li>     <li>The company expects total sales and comparable-store sales to range from -1% to +1% for the second half of the fiscal year.</li>     <li>Adjusted EBITDA expected to be in the range of $18M to $21M for the second half.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206069\" data-linked=\"More on Fred&#39;s Q2\" data-tweet=\"$FRED - More on Fred&#39;s Q2 https://seekingalpha.com/news/3206069-on-freds-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3206069-on-freds-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206061\" data-ts=\"1472559518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMDA\" target=\"_blank\">KMDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206061-mid-stage-study-of-kamadas-inhaled-aat-therapy-in-aatd-successful-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mid-stage study of Kamada&#39;s inhaled AAT therapy in AATD successful; shares up 7% premarket</a></h4><ul>\n<li>Thinly traded micro cap Kamada Ltd. (NASDAQ:<a href=\"https://seekingalpha.com/symbol/KMDA\" title=\"Kamada Ltd\">KMDA</a>) is up <font color=\"green\">7%</font> premarket on increased volume, albeit on turnover of only 44K shares, in response to its announcement of positive results in a Phase 2 clinical trial assessing its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), an orphan disease currently treated by intravenous AAT augmentation therapy.</li>\n<li>The double-blind, placebo-controlled study enrolled 36 AATD subjects. They were treated with Kamada's inhaled AAT therapy (80 mg/day or 160 mg/day) or placebo for 12 weeks during the double-blind period, after which eligible patients (n=26) entered into a 12-week open-label extension stage with the 160 mg/day dose to further assess safety and tolerability.</li>\n<li>The primary efficacy endpoints included antigenic AAT levels and Anti-Neutrophil Elastase Inhibitory (ANEC) levels in the lung as well as additional anti-proteolitic and anti-inflammatory biomarkers.</li>\n<li>Patients in the inhaled AAT therapy cohort showed a statistically significant increase in endothelial lining fluid (ELF) AAT antigenic level compared to placebo (p&lt;0.0005). The levels were more than twice the increase observed in an earlier study of intravenous (IV) AAT therapy. ELF ANEC levels also showed statistically valid increases for both doses and, again, were more than twice those observed with IV AAT.</li>\n<li>The company intends to initiated a pivotal study in the U.S. to confirm the results.</li>\n<li>\n<a href=\"https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency\" target=\"_blank\">AATD </a>is a rare inherited disorder that severely damages the lungs and liver.</li>\n<li>Related tickers: (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ARWR\" title=\"Arrowhead Pharmaceuticals\">ARWR</a>)(NASDAQ:<a href=\"https://seekingalpha.com/symbol/NTLA\" title=\"Intellia Therapeutics\">NTLA</a>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206061\" data-linked=\"Mid-stage study of Kamada&#39;s inhaled AAT therapy in AATD successful; shares up 7% premarket\" data-tweet=\"$KMDA $KMDA $ARWR - Mid-stage study of Kamada&#39;s inhaled AAT therapy in AATD successful; shares up 7% premarket https://seekingalpha.com/news/3206061-mid-stage-study-of-kamadas-inhaled-aat-therapy-in-aatd-successful-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3206061-mid-stage-study-of-kamadas-inhaled-aat-therapy-in-aatd-successful-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206060\" data-ts=\"1472559438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTO\" target=\"_blank\">VSTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206060-vista-outdoor-perks-up-after-keybanc-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vista Outdoor perks up after KeyBanc upgrade</a></h4><ul> <li>KeyBanc Capital Markets <a href=\"http://www.streetinsider.com/Analyst+Comments/KeyBanc+Upgrades+Vista+Outdoor+%28VSTO%29+to+Overweight/11984489.html\" target=\"_blank\">upgrades</a> Vista Outdoor (NYSE:<a href=\"https://seekingalpha.com/symbol/VSTO\" title=\"Vista Outdoor\">VSTO</a>) to an Overweight rating and assigns a price target of $48.</li> <li>The investment firm notes guns and ammunition demand could increase if Hillary Clinton were to win the election.</li> <li>VSTO <font color=\"green\">+1.83%</font> premarket to $40.10 vs. a 52-week trading range of $38.67 to $53.91.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3206060\" data-linked=\"Vista Outdoor perks up after KeyBanc upgrade\" data-tweet=\"$VSTO - Vista Outdoor perks up after KeyBanc upgrade https://seekingalpha.com/news/3206060-vista-outdoor-perks-up-after-keybanc-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3206060-vista-outdoor-perks-up-after-keybanc-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206054\" data-ts=\"1472558488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDLZ\" target=\"_blank\">MDLZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206054-mondelez-international-moves-higher-all-options-open\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mondelez International moves higher with all options open</a></h4><ul> <li>Mondelez International (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MDLZ\" title=\"Mondelēz International, Inc.\">MDLZ</a>) is higher after the company announced it pulled out of discussions with Hershey.</li> <li>Susquehanna analyst Pablo Zuanic thinks if the company wants to expand its confectionary and snacks footprint a merger with a European name (Lotte, Ferrero, or Perfetti Van Melle) or a smaller natural/organic player might make senses.</li> <li>Zuanic calls a merger with PepsiCo (NYSE:<a href=\"https://seekingalpha.com/symbol/PEP\" title=\"PepsiCo Inc.\">PEP</a>) more of a long shot and in the end thinks a takeover by Kraft Heinz (NASDAQ:<a href=\"https://seekingalpha.com/symbol/KHC\" title=\"The Kraft Heinz Company\">KHC</a>) might be the end result.</li> <li>MDLZ <font color=\"green\">+3.21%</font> premarket to $44.42.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206054\" data-linked=\"Mondelez International moves higher with all options open\" data-tweet=\"$MDLZ $MDLZ $PEP - Mondelez International moves higher with all options open https://seekingalpha.com/news/3206054-mondelez-international-moves-higher-all-options-open?source=tweet\" data-url=\"https://seekingalpha.com/news/3206054-mondelez-international-moves-higher-all-options-open\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206051\" data-ts=\"1472558003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCT\" target=\"_blank\">ARCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206051-alcobra-net-loss-widens-in-q2-shares-off-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcobra net loss widens in Q2; shares off 14%</a></h4><ul>\n<li>Alcobra (ADHD) Q2 results: Revenues: $0; R&amp;D Expense: $4.2M (+13.5%); SG&amp;A: $1.4M (+16.7%); Net Loss: ($5.8M) (-13.7%); Loss Per Share: ($0.21) (+12.5%); Quick Assets: $53.1M (+4.7%); CF Ops: ($4.1M) (-5.1%).</li>\n<li>No guidance given.</li>\n<li>Shares are down <font color=\"red\">14%</font> on a 5x surge in volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206051\" data-linked=\"Alcobra net loss widens in Q2; shares off 14%\" data-tweet=\"$ARCT - Alcobra net loss widens in Q2; shares off 14% https://seekingalpha.com/news/3206051-alcobra-net-loss-widens-in-q2-shares-off-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3206051-alcobra-net-loss-widens-in-q2-shares-off-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206050\" data-ts=\"1472557942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206050-abercrombie-fitch-falls-hard-after-weak-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abercrombie &amp; Fitch falls hard after weak outlook</a></h4><ul> <li>Shares of Abercrombie &amp; Fitch (NYSE:<a href=\"https://seekingalpha.com/symbol/ANF\" title=\"Abercrombie &amp; Fitch\">ANF</a>) slump after the company <a href=\"http://www.abercrombie.com/anf/investors/investorrelations.html\" target=\"_blank\">posted soft Q2 results</a> and cautioned on the back half.</li> <li>Same-store sales fell 4.0% during the quarter as traffic headwinds in the domestic mall business persisted and a lower level of tourism impacted results.</li> <li>SSS by brand: Abercrombie -7%, Hollister -1%.</li> <li>FY16 outlook from A&amp;F: \"Comparable sales to remain challenging through the second half of the year, with a disproportionate effect from flagship and tourist locations.\"</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3206047-abercrombie-and-fitch-misses-0_05-beats-revenue\" target=\"_blank\">Abercrombie &amp; Fitch misses by $0.05, beats on revenue</a> (Aug. 30)</li> <li>ANF <font color=\"red\">-11.29%</font> premarket to $20.36.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206050\" data-linked=\"Abercrombie &amp; Fitch falls hard after weak outlook\" data-tweet=\"$ANF - Abercrombie &amp; Fitch falls hard after weak outlook https://seekingalpha.com/news/3206050-abercrombie-fitch-falls-hard-after-weak-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3206050-abercrombie-fitch-falls-hard-after-weak-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206048\" data-ts=\"1472557915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIGL\" target=\"_blank\">RIGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206048-18-of-patients-in-rigel-pharmas-late-stage-study-of-fostamatinib-in-immune-thrombocytopenia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">18% of patients in Rigel Pharma&#39;s late-stage study of fostamatinib in immune thrombocytopenia achieve stable platelet count; rate of treatment-related adverse events 77%; shares up 5% premarket</a></h4><ul>\n<li>Micro cap Rigel Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/RIGL\" title=\"Rigel Pharmaceuticals, Inc.\">RIGL</a>) is up <font color=\"green\">5%</font> premarket on robust volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1034842/000110465916141998/a16-17640_1ex99d1.htm\" target=\"_blank\">announcement </a>of results from a Phase 3 clinical trial, Study 047, assessing lead product candidate fostamatinib for the treatment of immune thrombocytopenia (ITP), a bleeding disorder resulting from a person's immune system destroying blood platelets that affects ~60K people.</li>\n<li>76 participants were randomized 2:1 to receive either fostamatinib (100 mg twice daily)(n=51) or placebo (n=25). The primary endpoint was stable platelet count defined as platelet counts of at least 50K/uL on at least four of six visits between Weeks 14 and 24. All had chronic/persistent ITP (platelet levels &lt; 30K platelets/uL) and had received prior treatment.</li>\n<li>18% (n=9/51) achieved the primary endpoint compared to 0% for placebo, a statistically valid result.</li>\n<li>The rates of treatment-related adverse events (TRAEs) were 77% (n=39/51) for fostamatinib and 28% (n=2/25) for placebo. Most of the TRAEs for fostamatinib were gastrointestinal complaints (n=31/51 or 61%), specifically nausea, diarrhea, vomiting or abdominal pain. Other TRAEs were hypertension (35%) and <a href=\"https://en.wikipedia.org/wiki/Transaminase\" target=\"_blank\">transaminase </a>elevation (22%), a biomarker of liver stress/damage.</li>\n<li>\n<a href=\"http://www.rigel.com/index.php/fostamatinib-itp/\" target=\"_blank\">Fostamatinib </a>inhibits an enzyme called <a href=\"https://en.wikipedia.org/wiki/Syk\" target=\"_blank\">spleen tyrosine kinase</a> (SYK) that plays a key role in certain blood cancers and autoimmune disorders.</li>\n<li>Data from a second Phase 3 trial should be released soon.</li>\n<li>\n<strong>Update</strong>: <a href=\"https://slingshotinsights.com/\" target=\"_blank\">Slingshot Insights</a> has proposed an <a href=\"https://slingshotinsights.com/projects/289\" target=\"_blank\">expert interview</a> to discuss the data.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206048\" data-linked=\"18% of patients in Rigel Pharma&#39;s late-stage study of fostamatinib in immune thrombocytopenia achieve stable platelet count; rate of treatment-related adverse events 77%; shares up 5% premarket\" data-tweet=\"$RIGL - 18% of patients in Rigel Pharma&#39;s late-stage study of fostamatinib in immune thrombocytopenia achieve stable platelet count; rate of treatment-related adverse events 77%; shares up 5% premarket https://seekingalpha.com/news/3206048-18-of-patients-in-rigel-pharmas-late-stage-study-of-fostamatinib-in-immune-thrombocytopenia?source=tweet\" data-url=\"https://seekingalpha.com/news/3206048-18-of-patients-in-rigel-pharmas-late-stage-study-of-fostamatinib-in-immune-thrombocytopenia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206043\" data-ts=\"1472557254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206043-g-iii-apparel-lower-after-narrowing-fy2017-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G-III Apparel lower after narrowing FY2017 guidance</a></h4><ul>     <li>G-III Apparel (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GIII\" title=\"G-III Apparel Group, LTD.\">GIII</a>) reports gross margin rate fell 30 bps to 35.2% in Q2.</li>     <li>SG&amp;A expense rate grew 470 bps to 34.6%.</li>     <li>Inventory +13.7% to $634.58M.</li>     <li>\n<b>Q3 Guidance</b>: Net sales: ~$940M; Net income: $70M to $76M; Diluted EPS: $1.50 to $1.60.</li>     <li>\n<b>FY2017 Guidance</b>: Net sales: ~$2.48B; D&amp;A: $31.7M; Interest and financing charges, net: $7.3M; Income tax expense: $55M to $58M; Net income: $102M to $106M; Diluted EPS: $2.16 to $2.26; Adjusted EPS: $2.20 to $2.30; Adjusted EBITDA: $199M to $206M.</li>\n<li>GIII <font color=\"red\">-13.74%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3206043\" data-linked=\"G-III Apparel lower after narrowing FY2017 guidance\" data-tweet=\"$GIII - G-III Apparel lower after narrowing FY2017 guidance https://seekingalpha.com/news/3206043-g-iii-apparel-lower-after-narrowing-fy2017-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3206043-g-iii-apparel-lower-after-narrowing-fy2017-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3206028\" data-ts=\"1472555433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3206028-portolas-andexxa-effective-in-reversing-factor-xa-associated-bleeding-in-late-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola&#39;s AndexXa effective in reversing Factor Xa-associated bleeding in late-stage study; shares ahead 6% premarket</a></h4><ul>\n<li>Portola Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PTLA\" title=\"Portola Pharmaceuticals\">PTLA</a>) is up <font color=\"green\">6%</font> premarket, albeit on only 1,355 shares, in response to it announcement of positive interim results from a Phase 3b/4 study, ANNEXA-4, assessing the Factor Xa inhibitor antidote AndexXa (andexanet alfa) in reversing acute major bleeding associated with the anticoagulant. The data were presented today at the European Society of Cardiology Congress in Rome.</li>\n<li>A preliminary analysis on interim results from 67 patients (47 evaluated for efficacy) showed a 30-minute bolus of AndexXa rapidly and substantially reversed anti-Factor Xa activity and sustained the reversal when followed by a 120-minute infusion. The majority of patients (79%) achieved good or excellent hemostasis (bleeding stopped) over a 12-hour period after the infusion.</li>\n<li>Stuart Connolly, M.D., study Executive Committee chairman and professor in the Department of Medicine of the Faculty of Health Sciences at McMaster University in Hamilton, Ontario says, \"In this preliminary analysis, AndexXa was effective in rapidly reversing anti-Factor Xa inhibitor activity and restoring normal blood clotting in real-world patients with Factor Xa-related bleeding. Based on these interim results, we believe that ANNEXA-4 is on track to achieve its co-primary endpoints. The hemostatic efficacy results are especially important because no FDA- or EMA-approved antidote is available for these patients and no existing therapies, including plasma-derived products for warfarin reversal, have demonstrated reversal of Factor Xa inhibitor activity or clinical efficacy and safety.\"</li>\n<li>The interim data showed no AndexXa-associated infusion reactions and no patients developed antibodies to Factor Xa or Factor X or neutralizing antibodies to AndexXa. During the 30-day follow-up period, thrombotic events occurred in 12 patients (18%) while 10 patients died (15%), both within the expected range for this population.</li>\n<li>On August 17, the company received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for AndexXa. It plans to meet with the agency as soon as possible to resolve the issues and clarify a path forward. Its Marketing Authorization Application (MAA) is currently under review in Europe.</li>\n<li>Management will host a webcast today at 11:00 am ET to discuss the results.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3206028\" data-linked=\"Portola&#39;s AndexXa effective in reversing Factor Xa-associated bleeding in late-stage study; shares ahead 6% premarket\" data-tweet=\"$PTLA - Portola&#39;s AndexXa effective in reversing Factor Xa-associated bleeding in late-stage study; shares ahead 6% premarket https://seekingalpha.com/news/3206028-portolas-andexxa-effective-in-reversing-factor-xa-associated-bleeding-in-late-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3206028-portolas-andexxa-effective-in-reversing-factor-xa-associated-bleeding-in-late-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":41,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}